SMAD3 and glioblastoma: We then performed single-sample gene set enrichment analysis and found that survival was significantly shorter in patients with mesenchymal GBM and a higher Smad3 gene signature (a gene transcriptionally related to Smad3) than in those with mesenchymal GBM and a lower Smad3 signature (p = 0.001; Fig. 2C).